Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), was introduced as a novel medical therapy for uterine fibroids, offering sustained fibroid shrinkage, symptom relief, and better tolerability compared to traditional agents [3]. Here, PGR is linked to uterine corpus leiomyoma.